16 September 2024
16 September 2024
While Lykos Therapeutics’ MDMA therapy was rejected by the FDA, psychedelic therapy advocates remain optimistic about the sector.
The published belrestotug/dostarlimab data is still too immature to prove the combination’s capability to disrupt the NSCLC treatment paradigm.
Oncternal is halting the development of two cancer candidates, ONCT-534 and ONCT-808, after disappointing trial results.
GlobalData forecasts predict Enhertu will retain its dominant market position in the ADC treatment landscape.
The company plans to focus its resources on conducting clinical trials for CD388 influenza prevention therapy.
Distribution of the self-amplifying mRNA vaccine Kostaive is set to align with a planned October 2024 Covid-19 vaccination campaign.
The authorisation enables a twice-yearly, ten-minute subcutaneous injection to treat RMS and PPMS.
The safety profile of Dupixent in adolescents with moderate-to-severe asthma contributed to the FDA's decision.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
GlobalData's latest report provides a granular forecast growth analysis for both global and regional migraine markets through 2033. The report covers an exhaustive study of the countries wherein the market is prevalent, leading players, current treatment options, and factors driving the market growth. Furthermore, the pipeline valuation analysis and information on the market’s unmet needs and opportunities will help in determining potential business possibilities.
GlobalData's latest report provides a granular forecast growth analysis for both global and regional migraine markets through 2033. The report covers an exhaustive study of the countries wherein the market is prevalent, leading players, current treatment options, and factors driving the market growth. Furthermore, the pipeline valuation analysis and information on the market’s unmet needs and opportunities will help in determining potential business possibilities.
Give your business an edge with our leading industry insights.
